Clinical trials such as AURA3 and FLAURA have demonstrated that ctDNA analysis for EGFR mutations can serve as an early predictor of treatment response in patients with EGFR-mutant NSCLC [15,16]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.